Substance / Medication

Telaprevir

Overview

Active Ingredient
telaprevir
RxNorm CUI
1102261

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

1 trials linked to this intervention

1
Total Trials
0
Recruiting
0
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Efficacy and safety of telaprevir and boceprevir in patients with hepatitis C genotype 1: a meta-analysis.
Park C, Jiang S, Lawson K A · J Clin Pharm Ther · 2014
PMID: 24237070Meta-Analysis
Peg-interferon plus ribavirin with or without boceprevir or telaprevir for HCV genotype 1: a meta-analysis on the role of response predictors.
Coppola Nicola, Pisaturo Mariantonietta, Sagnelli Caterina et al. · PLoS One · 2014
PMID: 24728219Meta-AnalysisFull text (PMC)
[Meta-analysis of the efficacy and safety of telaprevir combined with peginterferon alfa plus ribavirin in patients with chronic hepatitis C].
Yan Shu-shan, Xu Dong-hua, Zhang Peng-jun et al. · Zhonghua Gan Zang Bing Za Zhi · 2013
PMID: 24074708Meta-Analysis
The relative efficacy of boceprevir and telaprevir in the treatment of hepatitis C virus genotype 1.
Kieran Jennifer, Schmitz Susanne, O'Leary Aisling et al. · Clin Infect Dis · 2013
PMID: 23074309Meta-Analysis
Telaprevir versus boceprevir in chronic hepatitis C: a meta-analysis of data from phase II and III trials.
Sitole Mugdha, Silva Matthew, Spooner Linda et al. · Clin Ther · 2013
PMID: 23369368Meta-Analysis
Efficacy and tolerability of telaprevir for chronic hepatitis virus C genotype 1 infection: a meta-analysis.
Kong Yuan, Wang Xiaoping, Shang Yushu et al. · PLoS One · 2012
PMID: 23284915Meta-AnalysisFull text (PMC)
Telaprevir for genotype 1 chronic hepatitis C: a systematic review and meta-analysis.
Gu Lian, Chen Qing, Xie Juanjuan et al. · Pharmazie · 2012
PMID: 23346756Meta-Analysis
Safety of telaprevir for chronic hepatitis C virus infection: a meta-analysis of randomized controlled trials.
Qin Huimin, Li Hongtao, Zhou Xiaolin et al. · Clin Drug Investig · 2012
PMID: 22889114Meta-Analysis
Formulary management of the protease inhibitors boceprevir and telaprevir for chronic hepatitis C virus.
Tungol Alexandra, Rademacher Kellie, Schafer Jeremy A · J Manag Care Pharm · 2011
PMID: 22050393Meta-AnalysisFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Telaprevir (substance)
SNOMED CT
698806003
UMLS CUI
C1876229
RxNorm CUI
1102261

Clinical Data

This intervention maps to 2 entities in the Healos knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
1
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.